132 related articles for article (PubMed ID: 27940223)
1. MOPS and coxsackievirus B3 stability.
Carson SD; Hafenstein S; Lee H
Virology; 2017 Jan; 501():183-187. PubMed ID: 27940223
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
3. New class of early-stage enterovirus inhibitors with a novel mechanism of action.
Ma Y; Abdelnabi R; Delang L; Froeyen M; Luyten W; Neyts J; Mirabelli C
Antiviral Res; 2017 Nov; 147():67-74. PubMed ID: 28993161
[TBL] [Abstract][Full Text] [Related]
4. Albumin Enhances the Rate at Which Coxsackievirus B3 Strain 28 Converts to A-Particles.
Carson SD; Cole AJ
J Virol; 2020 Feb; 94(6):. PubMed ID: 31915275
[TBL] [Abstract][Full Text] [Related]
5. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
Carson SD; Chapman NM; Hafenstein S; Tracy S
J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
[TBL] [Abstract][Full Text] [Related]
6. Three capsid amino acids notably influence coxsackie B3 virus stability.
Carson SD; Tracy S; Kaczmarek ZG; Alhazmi A; Chapman NM
J Gen Virol; 2016 Jan; 97(1):60-68. PubMed ID: 26489722
[TBL] [Abstract][Full Text] [Related]
7. The structure of coxsackievirus B3 at 3.5 A resolution.
Muckelbauer JK; Kremer M; Minor I; Diana G; Dutko FJ; Groarke J; Pevear DC; Rossmann MG
Structure; 1995 Jul; 3(7):653-67. PubMed ID: 8591043
[TBL] [Abstract][Full Text] [Related]
8. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
9. Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3.
Stadnick E; Dan M; Sadeghi A; Chantler JK
J Virol; 2004 Dec; 78(24):13987-4002. PubMed ID: 15564506
[TBL] [Abstract][Full Text] [Related]
10. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.
Dan M; Chantler JK
J Virol; 2005 Jul; 79(14):9285-95. PubMed ID: 15994822
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket.
Braun H; Kirchmair J; Williamson MJ; Makarov VA; Riabova OB; Glen RC; Sauerbrei A; Schmidtke M
Antiviral Res; 2015 Nov; 123():138-45. PubMed ID: 26391975
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site.
Yuan J; Stein DA; Lim T; Qiu D; Coughlin S; Liu Z; Wang Y; Blouch R; Moulton HM; Iversen PL; Yang D
J Virol; 2006 Dec; 80(23):11510-9. PubMed ID: 16987987
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
Kim JY; Jeon ES; Lim BK; Kim SM; Chung SK; Kim JM; Park SI; Jo I; Nam JH
Vaccine; 2005 Feb; 23(14):1672-9. PubMed ID: 15705471
[TBL] [Abstract][Full Text] [Related]
14. A single coxsackievirus B2 capsid residue controls cytolysis and apoptosis in rhabdomyosarcoma cells.
Gullberg M; Tolf C; Jonsson N; Polacek C; Precechtelova J; Badurova M; Sojka M; Mohlin C; Israelsson S; Johansson K; Bopegamage S; Hafenstein S; Lindberg AM
J Virol; 2010 Jun; 84(12):5868-79. PubMed ID: 20375176
[TBL] [Abstract][Full Text] [Related]
15. Structural Studies Reveal that Endosomal Cations Promote Formation of Infectious Coxsackievirus A9 A-Particles, Facilitating RNA and VP4 Release.
Domanska A; Plavec Z; Ruokolainen V; Löflund B; Marjomäki V; Butcher SJ
J Virol; 2022 Dec; 96(24):e0136722. PubMed ID: 36448797
[TBL] [Abstract][Full Text] [Related]
16. [The suppressive effect of MiR-490 on coxsackievirus B3 replication].
Wang LL; Zhong ZH; Wang Q; Lu P; Li M; Xu HY
Bing Du Xue Bao; 2014 Nov; 30(6):619-23. PubMed ID: 25868275
[TBL] [Abstract][Full Text] [Related]
17. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.
Schmidtke M; Wutzler P; Zieger R; Riabova OB; Makarov VA
Antiviral Res; 2009 Jan; 81(1):56-63. PubMed ID: 18840470
[TBL] [Abstract][Full Text] [Related]
18. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.
Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM
J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210
[TBL] [Abstract][Full Text] [Related]
19. Coxsackievirus B3 induces apoptosis in the early phase of murine myocarditis: a comparative analysis of cardiovirulent and noncardiovirulent strains.
Joo CH; Hong HN; Kim EO; Im JO; Yoon SY; Ye JS; Moon MS; Kim D; Lee H; Kim YK
Intervirology; 2003; 46(3):135-40. PubMed ID: 12867750
[TBL] [Abstract][Full Text] [Related]
20. Interactions between multiple genetic determinants in the 5' UTR and VP1 capsid control pathogenesis of chronic post-viral myopathy caused by coxsackievirus B1.
Sandager MM; Nugent JL; Schulz WL; Messner RP; Tam PE
Virology; 2008 Mar; 372(1):35-47. PubMed ID: 18029287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
